Floatz logo

Mrtx1719

Malignant Peripheral Nerve Sheath Tumors

Bristol-Myers SquibbPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Malignant Peripheral Nerve Sheath Tumors cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2B
Fludarabine
St. Jude Children's Research Hospital
Phase 2B
Pembrolizumab
Seattle Children's Hospital
Phase 1/2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 2CCC

View all 23 →

Same molecule, other indications

Mrtx1719 is also rated in:

cancerDormant
C
Indicative ·
39 / 100
View asset →
mesotheliomaDormant
C
Indicative ·
39 / 100
View asset →
pancreatic adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →